Other Income & Expense
Other Income (Expense)
United Therapeutics Other Income (Expense) decreased by 108.6% to -$7.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 118.4%, from $40.70M to -$7.50M. Over 2 years (FY 2023 to FY 2025), Other Income (Expense) shows an upward trend with a 57.4% CAGR.
Analysis
StatementIncome Statement
SectionOther Income & Expense
CategoryProfitability
SignalContext dependent
VolatilityModerate
First reportedQ1 2014
Last reportedQ1 2026
How to read this metric
An increase suggests higher non-operating gains or lower non-operating costs, while a decrease indicates higher non-operating expenses or lower non-operating income.
Detailed definition
Represents the net total of non-operating financial activities, including interest income, interest expense, foreign cur...
Peer comparison
Standard across all public companies; peers in the medical device sector often show similar volatility due to currency fluctuations.
Metric ID:
other_income_expense_netHistorical Data
18 periods
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$5.70M | -$24.30M | $20.70M | -$51.20M | -$1.80M | $7.50M | $21.80M | $24.80M | $35.30M | $42.30M | $35.40M | $45.50M | $38.80M | $40.70M | $43.90M | $49.50M | $87.30M | -$7.50M |
| QoQ Change | — | -326.3% | +185.2% | -347.3% | +96.5% | +516.7% | +190.7% | +13.8% | +42.3% | +19.8% | -16.3% | +28.5% | -14.7% | +4.9% | +7.9% | +12.8% | +76.4% | -108.6% |
| YoY Change | — | — | — | -798.2% | +92.6% | -63.8% | +142.6% | >999% | — | +464.0% | +62.4% | +83.5% | +9.9% | -3.8% | +24.0% | +8.8% | +125.0% | -118.4% |
Range-$51.20M – $87.30M
CAGR+6.7%
Avg YoY Growth+107.6%
Median YoY Growth+43.2%
Other Income (Expense) at Other Companies
Frequently Asked Questions
- What is United Therapeutics's other income (expense)?
- United Therapeutics (UTHR) reported other income (expense) of -$7.50M in Q1 2026.
- How has United Therapeutics's other income (expense) changed year-over-year?
- United Therapeutics's other income (expense) decreased by 118.4% year-over-year, from $40.70M to -$7.50M.
- What is the long-term trend for United Therapeutics's other income (expense)?
- Over 2 years (2023 to 2025), United Therapeutics's other income (expense) has grown at a 57.4% compound annual growth rate (CAGR), from $89.40M to $221.40M.
- What does other income (expense) mean?
- The net result of all income and expenses not related to core business operations.